B.Sc. (Biomedical Engineering), Tehran Polytechnic
M.Sc. (Biomedical Engineering), University of Tehran
Ph.D. (Biomedical Computing), Queen's University, Ontario
Assistant Professor, Faculty of Electrical and Computer Engineering, UBC
Mehdi Moradi completed a BSc degree in biomedical engineering from Tehran Polytechnic and an MSc degree in biomedical engineering from University of Tehran. In 2003, he came to Canada to work towards a Ph.D. in biomedical computing at Queen’s University in Kingston, Ontario. For the past decade, Dr. Moradi has focused on image-based solutions for improving the detection and treatment of prostate cancer. His broad research interests are machine learning in medical image analysis, image-guided therapy and diagnosis, and multimodality and multiparametric imaging with emphasis on MRI and ultrasound. During his PhD, Dr. Moradi developed a novel technology for detection of cancer from ultrasound echo signals. His work was recognized by several national research awards for its potential to improve the accuracy of targeting of tumors during prostate biopsy.
After finishing his PhD in 2008, Dr. Moradi came to UBC as an NSERC postdoctoral fellow. He contributed to the development of an ultrasound elastography system for interventional imaging of the prostate gland, developed a methodology for detection of prostate cancer from multiparametric MRI data, and designed and published an algorithm for fusion of X-ray and ultrasound for dosimetry during prostate brachytherapy. He left UBC in 2011 to work as a research scientist at the National Center for Image Guided Therapy within Harvard Medical School in Boston, MA where he developed a technic for registration of pre-operative MRI to ultrasound to improve intraoperative guidance of brachytherapy and biopsy under ultrasound imaging. He returned to UBC as an Assistant Professor in 2012 and joined the UBC Departments of Electrical and Computer Engineering and Urologic Sciences. The technologies Dr. Moradi applies to the problem are constantly evolving while he remains committed to his goal of improving quality of life for men with prostate cancer.